Biotech startup Irubis has successfully completed a pre-Series A funding round. The funding round was led by BioProcess360 Partners, with participation from early investors such as High-Tech Gründerfonds, Verve Ventures, Ventura BioMed Investors, RoBet KG, as well as new and existing business angels. The size of the round was not disclosed. With the funds, Irubis plans to further expand its innovative Monipa solution, which is designed to make bioprocesses more efficient and precise.
Irubis was founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler, and Anja Müller with the aim of automating the process development and manufacturing of biopharmaceutical drugs. The Munich startup developed its Monipa measurement system to bring biological active ingredients to market faster. The use of inline and online measurement methods aims to achieve higher yields and better quality, and enables automation of production for many life-saving medicines. This innovative approach gives Monipa an advantage over conventional technologies.
Funds for the next crucial steps
Anja Müller, CEO and co-founder of Irubis, comments on the current funding round:
“The pre-Series A round supports Irubis in taking the next crucial steps, including improving Good Manufacturing Practices (GMP) of our Monipa technology and expanding its applications in ultra-/diafiltration (UF/DF) and other downstream process steps. Additionally, we are focused on increasing our market presence and are proud to work with more than half of the industry’s key opinion leaders and strengthen our position in the biopharmaceutical sector.”
And Chris Major from BioProcess360 adds:
“I have truly enjoyed building a relationship with the founders of this incredible technology. At BioProcess360, we are committed to driving life-improving bioprocess technologies to success, both with capital and, more importantly, with expert guidance for our investments to ensure these mission-critical tools can succeed. We are enthusiastic about Irubis’s mission and look forward to actively and practically supporting the company in developing and implementing a successful growth strategy to achieve its goals. ATR single-use crystals will play a crucial role in many areas of traditional mAb therapies, but especially in newer modalities such as gene therapy, bispecific antibodies, antibody-drug conjugates (ADC), and nucleic acids.”
In October 2022, Irubis already secured seed funding of 2.8 million euros. Investors in this round included High-Tech Gründerfonds, Verve Ventures and Ventura BioMed as well as EIC Fund, Initiative for Industrial Innovators and other business angels from the biotech industry or the Munich startup scene.
